1201903-02-7

Basic information

• Product Name: Ixazomib Impurity 1
• Synonyms: Ixazomib Impurity 1;2,5-dichloro-N-(2-(((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-2-oxoethyl)benzamide
• CAS NO: 1201903-02-7
• Molecular Formula: C₂₄H₃₃BCl₂N₂O₄
• Molecular Weight: 495.24682
• Mol File: 1201903-02-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane; Chloroform; Methanol; Ethyl Acetate; DMSO
• CAS DataBase Reference: Ixazomib Impurity 1(CAS DataBase Reference)
• NIST Chemistry Reference: Ixazomib Impurity 1(1201903-02-7)
• EPA Substance Registry System: Ixazomib Impurity 1(1201903-02-7)

Safety Data

• Hazardous Substances Data: 1201903-02-7(Hazardous Substances Data)

Usage

Description

Ixazomib Impurity 1, also known as 2,5-Dichloro-N-[2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-2-oxoethyl]-benzamide, is an intermediate compound used in the synthesis of Ixazomib (I942000). Ixazomib is a proteasome inhibitor that prevents cell growth in solid tumors, making it an effective anticancer agent. It is primarily used to treat patients with multiple myeloma and has potential neurotoxic effects.

Uses

Used in Pharmaceutical Industry:
Ixazomib Impurity 1 is used as an intermediate in the synthesis of Ixazomib, an anticancer agent, for its role in preventing cell growth in solid tumors.
Ixazomib Impurity 1 is used as a component in the development of proteasome inhibitors for the treatment of multiple myeloma patients, due to its contribution to the overall synthesis process of Ixazomib.
Additionally, Ixazomib Impurity 1 plays a role in the study and understanding of the potential neurotoxic effects of Ixazomib, as it is an integral part of the synthesis pathway.

Upstream product

• 18680-27-8 pinanediol 
• 667403-46-5 2-[(2,5-dichlorobenzoyl)amino]acetic acid 
• 779357-85-6 (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxabor-ol-2-yl]butan-1-amine hydrochloride 
• 85167-14-2 (3aS,4S,6S,7aR)-2-[(1S)-1-chloro-3-methylbutyl]-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole 
• 84110-34-9 2-(2-methylpropyl)-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole 
• 1310383-72-2 (aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-α-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate 
• 50-79-3 2,5-dichlorobenzoic acid 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 
• 2905-61-5 2,5-dichlorobenzoyl chloride 

Downstream Products

• 1201903-03-8 Ν,Ν',Ν''-[boroxin-2,4,6-triyltris[[(1R)-3-methylbutane-1,1-diyl]imino(2-oxoethane-2,1-diyl)]]tris(2,5-dichlorobenzamide) 
• 1239908-20-3 2,2’-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid 
• 1072833-77-2 Ixazomib 

Relevant articles and documents

Virtues of Volatility: A Facile Transesterification Approach to Boronic Acids

Boronic acids are an increasingly important compound class for many applications, including C-C bond formation reactions, medicinal chemistry, and diagnostics. The deprotection of boronic ester intermediates is frequently a problematic and inefficient step in boronic acid syntheses. We describe an approach that highly facilitates this transformation by leveraging the volatility of methylboronic acid and its diol esters. The method is performed under mild conditions, provides high yields, and eliminates cumbersome and problematic purification steps.

NOVEL CRYSTALLINE FORMS OF IXAZOMIB CITRATE AND ITS PROCESS FOR PREPARATION THEREOF

The present invention related to novel crystalline forms of Ixazomib citrate of formula-I and its process for preparation thereof. The chemical structure of said compound represented by the following formula-I. This invention also provides a process for the preparation of Ixazomib citrate of formula-I and also its solid dispersions.

Preparation process method for boron-containing compound

The invention discloses a preparation method for a boron-containing compound MLN2238. The method for preparing the MLN2238, disclosed by the invention, comprises the steps of adopting a solid compound intermediate II, which is stable in properties and can be subjected to recrystallization and purification, as an intermediate node for quality control, carrying out recrystallization or pulping purification on the intermediate, and then, carrying out a next-step reaction, thereby obtaining the boron-containing compound MLN2238 with relatively high purity. The synthesis process route is free of special requirements on production equipment, the reaction conditions are mild, and all the raw materials are all marketable products, so that the process route is very applicable to industrial production.